1. Hedgehog Pathway Inhibitors Pipeline Insights, 2021 What are Hedgehog Pathway Inhibitors? Hedgehog pathway inhibitors are small molecules that inhibit the activity of a component of the Hedgehog signaling pathway. Due to the role of aberrant Hedgehog signaling in tumor progression and cancer stem cell maintenance across cancer types, inhibition of the Hedgehog signaling pathway is usually a useful strategy for restricting tumor growth and for preventing the recurrence of the disease post-surgery, or post- chemotherapy. DelveInsight launched a new report on “Hedgehog Pathway Inhibitors - Pipeline Insight, 2021.’ The report provides comprehensive insights about key companies and pipeline drugs in Hedgehog Pathway Inhibitors pipeline landscape. The report covers the pipeline drug profiles, including clinical and nonclinical stage products, therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products during this space. Request for sample pages of the report: https://www.delveinsight.com/sample-request/hedgehog-pathway- inhibitors-pipeline-insight Hedgehog Pathway Inhibitors Causes and Side Effects Adverse events (AEs) commonly observed in hedgehog pathway inhibitor (HPI)-treated patients include muscle spasms, ageusia/dysgeusia, alopecia, weight loss, and asthenia

2. (fatigue). These AEs are thought to be mechanistically associated with inhibition of the hedgehog pathway in normal tissue. Hedgehog Pathway Inhibitors Market Key Insights ●The total Hedgehog Pathway Inhibitors market size was USD XX million in 2018. ●The Hedgehog Pathway Inhibitors market size shall increase during the forecast period (2018–2030) due to the launch of upcoming therapies. ●The US accounted for XX% of the Hedgehog Pathway Inhibitors market size in 2018. ●The Hedgehog Pathway Inhibitors market size was USD XX million in 2018. According to DelveInsight, the Hedgehog Pathway Inhibitors Market in 7MM is expected to change. Got queries? Click here to get insights into Hedgehog Pathway Inhibitors Pipeline Insights Hedgehog Pathway Inhibitors Emerging Therapy Assessment The plethora of kinase inhibitors is currently in Phase II and Phase III stage of clinical development for various indications. Some of the major key pharma players include: 1.NLM-001 by Nelum Pharmaceuticals 2.Patigetib by PellePharm 3.SUBA-itraconazole by Mayne Pharma 4.IMP5471 by Impact Therapeutics The emerging therapy assessment segment of the Hedgehog Pathway Inhibitors report encloses an in-depth analysis of Hedgehog Pathway Inhibitors marketed drugs and late-stage pipeline drugs.